Speaker line-up of 2023
Ainhoa Lucía Quintana
Assistant Professor, University of Zaragoza
Alberto Bresciani
Director of Project Biology, Exscientia
Alexandra Cameron
Senior Expert, Unit Head A.I. Impact Initiatives and Research Coordination, AMR Division, World Health Organization
Amir Nakar
Scientific Affairs Specialist, MeMed
Anand Anandkumar
Chief Executive Officer, Bugworks Research Inc.
Anders Karlén
Professor in Computer-Aided Drug Design
Athanasios Typas
Group Leader & Senior Scientist, European Molecular Biology Laboratory
Bernhard Kerscher
Head of Laboratory & Preclinical Assessor, Paul-Ehrlich-Institut - German Federal Institute for Vaccines and Biomedicines
Betsy Wonderly Trainor
Alliance Director Diagnostics, CARB-X
Beverly Isherwood
Partnership Lead, Medicines Discovery Catapult
Bita Sehat
Senior Investment Director, Trill Impact
Camilla Rodrigues
Consultant Microbiologist & Chair Infection Control, Hinduja Hospital Mumbai
Chantal Morel
Health economist in anti-microbial resistance, KPM Center for Public Management, University of Bern
Christian Röhrig
Program Director, Micreos
Christoph Dehio
Full Professor of Molecular Microbiology, Director of National Centre of Competence in Research (NCCR) “AntiResist”
Cornelis Boersma
Professor Sustainable Health and Innovation, Netherlands Antibiotic Development Platform (NADP)
David Cameron
Senior Scientist, Debiopharm International S.A.
David Paterson
Professor ADVANCE-ID, National University of Singapore
Deborah O’Neil
CEO, NovaBiotics Ltd & Board Member, BEAM Alliance
Delphine Croisier
CEO, VIVEXIA
Dominic O’Neil
Director Microbiome Product Development, QIAGEN GmbH
Dominik Gary
Chief Development Officer, fzmb GmbH - Research Center for Medical Technology and Biotechnology
Douglas Häggström
Manager INCATE, University of Basel
Ed Buurman
Alliance Director CARB-X
Fei Shen
Managing Director, Boehringer Ingelheim Venture Fund USA
Flic Gabbay
Founding Partner, tranScrip
Florence Séjourné
CEO, Aurobac Therapeutics & Treasurer, BEAM Alliance
Giancarlo Biagini
Head of the Department of Tropical Disease Biology, Liverpool School of Tropical Medicine
Glenn E. Dale
Chief Development Officer, BioVersys AG
Hasan Jafri
Chief Medical Officer, Aridis Pharmaceuticals Inc.
Hatim Sati
Public Health Technical Officer, World Health Organization
Jaideep Gogtay
Global Chief Medical Officer, Ciplay Ltd
James Anderson
Executive Director of Global Health, IFPMA
Jan Poolman
Vice-President, Head Bacterial Vaccine Discovery and Early Development, Janssen Vaccines & Prevention B.V.
Jeroen Nieuwland
CSO and Co-founder, Llusern Scientific
Jitao David Zhang
Computational Biologist, F. Hoffmann-La Roche Ltd.
Joël Denis
Director General, Antimicrobial Resistance Task Force, Public Health Agency of Canada
John Alter
Head of External Affairs, AMR Action Fund
John Rex
Chief Medical Officer, F2G Ltd. & Operating Partner, Advent Life Sciences
Kamini Walia
Senior Scientist at Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research
Kevin Outterson
Austin B Fletcher Professor, Boston University, and Executive Director & Principal Investigator, CARB-X
Kristine Peers
General Counsel, EFPIA
Kwangmin Son
Co-founder and CEO, PhAST
Marc Gitzinger
CEO, BioVersys AG & President, BEAM Alliance
Maria Uria-Nickelsen
Alliance Director, CARB-X
Mariano Votta
Responsible EU Affairs at Cittadinanzattiva and Director Active Citizenship Network
Mark Jones
Head of Development, Basilea Pharmaceutica International Ltd | BEAM Alliance - Board Member | Swiss Round Table for Antibiotics - Board Member
Marlieke De Kraker
Senior epidemiologist, Geneva University Hospitals and Faculty of Medicine
Martin Heidecker
Chief Investment Officer, AMR Action Fund
Martin J. Boeree
Professor in clinical tuberculosis, Radboud universitair medisch centrum
Morgane Vanbiervliet
Manager, Market Intelligence & Business Development, Infectious Diseases, Debiopharm International SA
Natalie D’Amore
Head of External Innovation, Seres Therapeutics
Nikolaus Stiefl
Director Data Science, GDC CADD, Novartis Institutes for BioMedical Research (NIBR)
Norbert Heinrich
Unit head for TB diagnostic and treatment trials, Ludwig-Maximilians-University of Munich
Peter Jackson
Executive director, Infex Therapeutics
Rachel Silverman Bonnifield
Senior Fellow, Center for Global Development
Radu Botgros
Senior Scientific Officer, European Medicines Agency
Rakel Arrazuria
Researcher, Microbiology Division, Paul-Ehrlich-Institut - German Federal Institute for Vaccines and Biomedicines
Ralf Sudbrak
Interim Secretariat Lead, Global AMR R&D Hub
Remko van Leeuwen
CEO, SurvivX
Samuel Schumacher
Scientist, WHO Global TB Programme
Santiago Ferrer Bazaga
Investigator and Scientific Advisor for Drug Discovery, Universidad Carlos III de Madrid
Seamus O’Brien
R&D Director, GARDP
Shampa Das
Deputy Head of Department of Pharmacology and Therapeutics, University of Liverpool
Steve Brooks
Advisor and Manufacturing Work Group Lead, AMR Industry Alliance
Su Chiang
Senior Alliance Manager, CARB-X, Boston University
Taslimarif Saiyed
Director and CEO, Centre for Cellular and Molecular Platforms
Tetsuya Itani
Director, Office of Global Health Cooperation, Ministry of Health, Labour and Welfare, Japan
Theresa Liebe
Assay Developer, BLINK AG
Todd Young
Senator, US Congress
Urs Jenal
Professor of Infection Biology, University of Basel & Co-director of NCCR AntiResist
Ursula Theuretzbacher
Founder, Center for Anti-Infective Agents
Valeria Gigante
Team Lead AMR Division, World Health Organization
Werner J. Heinz
Head of the Medical Clinic II, Caritas Hospital
Wolfgang Philipp
Acting Deputy Head HERA, European Commission
Yann Ferrisse
Director, Business Development & Partner Engagement, Global Access at Global Antibiotic R&D Partnership (GARDP)
Zemer Gitai
EG Conklin Professor, Department of Molecular Biology, Princeton University and Founder, ArrePath Inc.